Precision-AD - About the company
Precision-AD is an unfunded company based in Nashville (United States), founded in 2026. It operates as a Developer of targeted therapeutics and companion diagnostics for Alzheimer disease. Precision-AD has not raised any funding yet. The company has 173 active competitors, including 53 funded and 17 that have exited. Its top competitors include companies like Insightec, Drug Farm and LEXEO Therapeutics.
Company Details
Developer of targeted therapeutics and companion diagnostics for Alzheimer disease. This organization integrates human multi-omic and clinical data to identify biological mechanisms driving distinct forms of the condition. By mapping patient subtypes, the platform advances therapeutic interventions and clinical trial enrichment strategies designed to align specific treatments with patient biology. The approach focuses on vascular, immune, and neuronal pathways to move beyond traditional diagnostic models.
Key Metrics
Sign up to download Precision-AD's company profile
Precision-AD's funding and investors
Precision-AD has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Precision-AD's Competitors and alternates
Top competitors of Precision-AD include Insightec, Drug Farm and LEXEO Therapeutics. Here is the list of Top 10 competitors of Precision-AD, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Manufacturer of focused ultrasound platforms for treating neurological movement disorders | $574M | 67/100 | ||
2nd | Developer of a novel treatment for metabolic diseases | $138M | 65/100 | ||
3rd |  LEXEO Therapeutics 2018, New York City (United States), Public | Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases | $185M | 64/100 | |
4th |  OncoC4 2020, Rockville (United States), Series B | Developer of immunotherapy for cancer patients | $50M | 62/100 | |
5th | Longeveron 2014, Miami (United States), Public | Developer of cellular therapies for aging-related and life-threatening conditions | $1.05M | 56/100 | |
6th |  RUBEDO LIFE SCIENCES 2018, Sunnyvale (United States), Series A | Developer of therapeutics for age-related diseases | $52M | 61/100 | |
7th | Cassava Sciences 1998, Austin (United States), Public | Developer of small molecule-based therapeutic solutions for treating neurological diseases | - | 60/100 | |
8th | Acumen Pharmaceuticals 1996, Livermore (United States), Public | Developer of monoclonal antibody therapeutics for Alzheimer's disease | $2.2M | 59/100 | |
9th | Developer of devices for neurodegenerative diseases | $25.2M | 58/100 | ||
10th | Alzheon 2013, Framingham (United States), Series E | Developer of disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders | $274M | 58/100 | |
200th | Precision-AD 2026, Nashville (United States), Unfunded | Developer of targeted therapeutics and companion diagnostics for Alzheimer disease | - | - | - |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Precision-AD's competitors? Click here to see the top ones
Precision-AD's Investments and acquisitions
Precision-AD has made no investments or acquisitions yet.
Reports related to Precision-AD
Here is the latest report on Precision-AD's sector:
Are you a Founder ?
FAQs about Precision-AD
Explore our recently published companies
- GTMMaxing - 2025 founded, Unfunded company
- Guardian Angel Employment - Singapore based, 2026 founded, Unfunded company
- GRW Advisory - 2026 founded, Unfunded company
- Guhan Group - Bengaluru based, 2026 founded, Unfunded company
- Guardiao Azul - Brazil based, 2026 founded, Unfunded company
- GTM Quest - London based, 2024 founded, Unfunded company
